Those who have been here a while will remember that when the poloxamer 188 drug was acquired, it was stated that the solution to the Clinical Trial negative effects was thought to be "a failure on the manufacturer's part to provide a proper level of purification". The success of the 64 patient QT/QTc trial has verified that evaluation.
What we have now is a safe drug that was found to be "generally well-tolerated at both therapeutic and supratherapeutic doses", that has been granted Orphan Drug Designation for pediatric SCD (Sickle Cell Disease).
This first hurdle has been eliminated now and what remains is verification of the data which has been derived from over 100 pharmacology studies, more than 15 clinical studies in multiple indications in which over 2,500 subjects have been exposed to both purified and non-purified poloxamer 188, and over two decades of experience manufacturing and purifying poloxamers.
Sentiment: Strong Buy